Leslie Hanrahan
Overview
Explore the profile of Leslie Hanrahan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Birt J, Hadi M, Sargalo N, Brookes E, Swinburn P, Hanrahan L, et al.
Rheumatol Ther
. 2021 Jun;
8(3):1189-1205.
PMID: 34164800
Objectives: To provide information on systemic lupus erythematosus (SLE) patients' experiences, satisfaction, and expectations with treatments and examine the association between treatment satisfaction and patient-reported outcomes (PRO). Methods: A cross-sectional,...
2.
Kim M, Merrill J, Wang C, Viswanathan S, Kalunian K, Hanrahan L, et al.
Lupus Sci Med
. 2019 Oct;
6(1):e000348.
PMID: 31649825
Objective: A common problem in clinical trials is missing data due to participant dropout and loss to follow-up, an issue which continues to receive considerable attention in the clinical research...
3.
Manzi S, Raymond S, Tse K, Pena Y, Anderson A, Arntsen K, et al.
Lupus Sci Med
. 2019 Aug;
6(1):e000342.
PMID: 31413854
Objective: Lupus is a complex, heterogeneous autoimmune disease that has yet to see significant progress towards more timely diagnosis, improved treatment options for short-term and long-term outcomes, and appropriate access...
4.
Wallace D, Tse K, Hanrahan L, Davies R, Petri M
Lupus Sci Med
. 2019 Jun;
6(1):e000317.
PMID: 31168400
The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the...
5.
Kim M, Merrill J, Kalunian K, Hanrahan L, Izmirly P
Lupus Sci Med
. 2018 Oct;
5(1):e000266.
PMID: 30319781
Objective: To evaluate response duration and identify predictors of transitioning into and out of the response state in patients with SLE receiving standard of care (SoC) in 52-week clinical trials....
6.
Merrill J, Manzi S, Aranow C, Askanase A, Bruce I, Chakravarty E, et al.
Lupus Sci Med
. 2018 Apr;
5(1):e000258.
PMID: 29657738
Formidable impediments stand in the way of treatment development for lupus. These include the unwieldy size of current trials, international competition for scarce patients, complex outcome measures and a poor...
7.
Askanase A, Li X, Pong A, Shum K, Kamp S, Carthen F, et al.
Lupus Sci Med
. 2015 Apr;
2(1):e000075.
PMID: 25861457
Objective: Current disease activity measures for systemic lupus erythematosus (SLE) are difficult to score or interpret and problematic for use in clinical practice. Lupus Foundation of America (LFA)-Rapid Evaluation of...